Chronic Myelomonocytic Leukemia

Differentiating CMML from other MPNs and MDS can be challenging due to overlapping features. Key distinctions include persistent monocytosis (absolute monocyte count >1 x 10^9/L), absence of the BCR-ABL1 fusion gene (excluding CML), and dysplasia in one or more myeloid lineages. While MPNs often present with higher white blood cell counts and specific genetic markers, MDS typically shows more significant dysplasia and less pronounced monocytosis. Bone marrow biopsy and cytogenetic analysis are crucial for accurate diagnosis. Specific molecular markers, such as ASXL1, TET2, and SRSF2 mutations, can further support CMML diagnosis and risk stratification. Explore how integrating molecular testing can enhance CMML diagnostic accuracy and prognostication.

Treatment for CMML depends on the subtype (CMML-1 vs. CMML-2), disease progression, and patient-specific factors. For CMML-1, with less than 10% blasts in the peripheral blood and bone marrow, treatment is primarily supportive, focusing on managing symptoms and cytopenias. Consider implementing strategies like erythropoiesis-stimulating agents or transfusions as needed. In contrast, CMML-2, characterized by 10-19% blasts or Auer rods, warrants more aggressive intervention, such as hypomethylating agents (azacitidine or decitabine) or intensive chemotherapy, especially for patients eligible for allogeneic stem cell transplantation (allo-HSCT). Learn more about the evolving role of targeted therapies and novel treatment approaches in CMML management based on specific molecular profiles.

Several prognostic factors help determine the course and outcome of CMML. The most established system is the CMML-Specific Prognostic Scoring System (CPSS), which incorporates factors like blast percentage, hemoglobin levels, platelet count, and karyotype abnormalities. Higher blast percentage, lower hemoglobin and platelet counts, and adverse karyotype are associated with worse prognosis. Additional molecular markers, including ASXL1, TET2, and RUNX1 mutations, have emerged as significant prognostic indicators. Furthermore, the revised CPSS-Revised (CPSS-R) integrates these mutations to refine risk stratification and treatment decisions. Consider implementing CPSS-R in your practice for more accurate prognostication in CMML patients and to guide individualized treatment strategies.